What is PF-06939999 dose escalation used for?

PF-06939999 dose escalation is indicated for Spinal muscular atrophy with two copies of a healthy SMN2 gene, Spinal muscular atrophy with two copies of a healthy SMN2 gene, Spinal muscular atrophy with two copies of a healthy SMN2 gene, Spinal muscular atrophy with two copies of a healthy SMN2 gene, Spinal muscular atrophy with two copies of a healthy SMN2 gene.

Who makes PF-06939999 dose escalation?

PF-06939999 dose escalation is developed by Pfizer.

What development phase is PF-06939999 dose escalation in?

PF-06939999 dose escalation is FDA-approved (marketed).

What is the generic name of PF-06939999 dose escalation?

pf-06939999-dose-escalation is the generic (nonproprietary) name of PF-06939999 dose escalation.

Last reviewed 2026-04-20 · How we verify

PF-06939999 dose escalation (pf-06939999-dose-escalation)

Pfizer · FDA-approved discontinued Quality 40/100

PF-06939999 dose escalation is a marketed drug by Pfizer for spinal muscular atrophy in patients with two copies of a healthy SMN2 gene. The key composition patent expires in 2028, providing a period of market exclusivity. However, the drug faces competition from other therapies such as Dabrafenib, Vemurafenib, Cobimetinib, and Selumetinib, which may limit its market share.

At a glance

Generic name	pf-06939999-dose-escalation
Sponsor	Pfizer
Drug class	Not specified
Target	Not specified
Therapeutic area	Other
Phase	FDA-approved

Approved indications

Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Spinal muscular atrophy with two copies of a healthy SMN2 gene

Common side effects

No common side effects on file.

Drug interactions

Warfarin
P-glycoprotein inhibitors
P-glycoprotein inducers
Strong CYP3A4 inhibitors
Strong CYP3A4 inducers

Key clinical trials

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-06939999 dose escalation CI brief — competitive landscape report
PF-06939999 dose escalation updates RSS · CI watch RSS
Pfizer portfolio CI